Opposing role of phagocytic receptors MERTK and AXL in Progranulin deficient FTD.

TitleOpposing role of phagocytic receptors MERTK and AXL in Progranulin deficient FTD.
Publication TypeJournal Article
Year of Publication2025
AuthorsClelland CDudley, Fan L, Saloner R, Etchegaray JIker, Altobelli CRichard, Salomonsson S, Maltos AM, Sachdev A, Zhu J, Lee S-I, Li Y, Zhou Y, Le D, Wang C, Carling G, Kodama L, Sayed F, Perez-Bermejo JA, Geier EG, Yokoyama JS, Rosen H, Nana AL, Spina S, Grinberg LT, Seeley WW, Elahi F, Boxer AL, Arkin MR, Gan L
JournalCommun Biol
Volume8
Issue1
Pagination971
Date Published2025 Jul 01
ISSN2399-3642
KeywordsAnimals, Axl Receptor Tyrosine Kinase, c-Mer Tyrosine Kinase, Female, Frontotemporal Dementia, Humans, Male, Mice, Mice, Knockout, Microglia, Mutation, Phagocytosis, Progranulins, Proto-Oncogene Proteins, Receptor Protein-Tyrosine Kinases
Abstract

Genetic mutations in the progranulin gene, GRN, cause frontotemporal dementia and a lysosomal storage disorder. Using single-nuclei RNA sequencing of the post-mortem brain tissue from adult heterozygous pathogenic granulin variant (GRN+/-) carriers we find dysregulation of microglia, phagocytosis and the phagocytic receptors MERTK and AXL. Exogenous progranulin regulates MERTK and AXL RNA expression in human microglia induced from iPSCs irrespective of GRN mutation status, without directly binding to MERTK or AXL proteins. We generated double knock-out mice and find that constitutive homozygous loss of Grn and Mertk (Grn-/-;Mertk-/-) rescued microglial disease signature while constitutive homozygous loss of Grn and Axl (Grn-/-;Axl-/-) worsened the microglial disease signature and increased lipofuscin. Lower CSF MERTK but not AXL is associated with lower progranulin levels. Furthermore, CSF MERTK is lower in symptomatic but not presymptomatic FTD patients with genetic mutations (GRN, C9ORF72, and MAPT) whereas AXL does not change between disease state and control. These data explain in part the inflammation seen in GRN-FTD and are applicable to other inflammatory states in which PGRN, MERTK and AXL play regulatory roles beyond neurodegenerative diseases. The interaction between GRN, MERTK, and AXL opens potential new therapeutic avenues to intervene on this inflammatory axis.

DOI10.1038/s42003-025-08368-2
Alternate JournalCommun Biol
PubMed ID40596721
PubMed Central IDPMC12218935
Grant ListU54 NS100717 / NS / NINDS NIH HHS / United States
U24 AG021886 / AG / NIA NIH HHS / United States
U01 AG057195 / AG / NIA NIH HHS / United States
U19 AG063911 / AG / NIA NIH HHS / United States
K08 NS112330 / NS / NINDS NIH HHS / United States
R01 AG074541 / AG / NIA NIH HHS / United States
P30 AG062422 / AG / NIA NIH HHS / United States
P01 AG019724 / AG / NIA NIH HHS / United States
TL1 TR001871 / TR / NCATS NIH HHS / United States
R01 AG072758 / AG / NIA NIH HHS / United States
R01 AG054214 / AG / NIA NIH HHS / United States
U01 AG045390 / AG / NIA NIH HHS / United States
U54 NS092089 / NS / NINDS NIH HHS / United States